newsfilter
← Latest News
GlobeNewswire·

Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

Dosing initiated in healthy participants in Phase 1a/b trial for ABI-5366 targeting recurrent genital herpes, with interim Phase 1a first-in-human data expected in Q3 2024 and interim Phase 1b data in participants with